Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EUDRAct No: 2005-006167-31 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2-3 years tamoxifen
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | 6 years adjuvant anastrozole therapy |
|
| 2 | Experimental | 3 years adjuvant anastrozole therapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anastrozole | Drug | 1 mg once daily oral dose |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| To assess the disease free survival (DFS) with 6 years of adjuvant anastrozole compared with 3 years of adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2 to 3 years of adjuvant tamoxifen | After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen |
| Measure | Description | Time Frame |
|---|---|---|
| To compare the incidence of contralateral breast cancer after 6 years versus 3 years adjuvant anastrozole, subsequent to 2 to 3 years of tamoxifen | After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| AstraZeneca Netherlands Medical Director, MD | AstraZeneca | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | 's-Hertogenbosch | Netherlands | ||||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36992863 | Derived | Tjan-Heijnen VCG, Lammers SWM, Geurts SME, Vriens IJH, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, de Roos WK, Linn SC, Imholz ALT; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators. Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial. EClinicalMedicine. 2023 Mar 20;58:101901. doi: 10.1016/j.eclinm.2023.101901. eCollection 2023 Apr. | |
| 30748011 |
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Oct 31, 2016 | Jul 4, 2017 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| To compare the overall survival after 6 years versus 3 years adjuvant anastrozole, subsequent to 2 to 3 years of tamoxifen |
| After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen |
| To compare toxicity of 6 years versus 3 years of adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2 to 3 years of tamoxifen | After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen |
| To determine regional differences in the initial treatment of breast cancer retrospectively by collecting baseline information on initial therapies. | Aspects of the initial treatment that will be investigated are e.g. the kind of surgery performed (breast saving or mastectomy) and whether or not chemotherapy is given and which chemotherapy was used in postmenopausal patients in relation to the primary tumour and patient characteristics. | After 9 years |
| To compare the cost effectiveness of 3 years versus 6 years adjuvant anastrozole therapy, after subsequent 2 to 3 years of adjuvant tamoxifen treatment. | After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen |
| To assess patterns of care in The Netherlands in prevention, detection and treatment of osteoporosis in postmenopausal women with breast cancer treated with adjuvant anastrozole. | After 9 years |
| To relate the number of osteoporotic fractures during and following treatment with adjuvant anastrozole with the compliance to osteoporotic guidelines. | After 9 years |
| To analyse occurrence of distant (bone) metastases in relation to occurrence of osteopenia and osteoporosis, and in relation to use of supplements and therapy for reduced BMD. | After 9 years |
| Alkmaar |
| Netherlands |
| Research Site | Almelo | Netherlands |
| Research Site | Almere Stad | Netherlands |
| Research Site | Amersfoort | Netherlands |
| Research Site | Amstelveen | Netherlands |
| Research Site | Amsterdam | Netherlands |
| Research Site | Apeldoorn | Netherlands |
| Research Site | Arnhem | Netherlands |
| Research Site | Bergen op Zoom | Netherlands |
| Research Site | Beugen | Netherlands |
| Research Site | Breda | Netherlands |
| Research Site | Capelle aan den IJssel | Netherlands |
| Research Site | Deventer | Netherlands |
| Research Site | Dirksland | Netherlands |
| Research Site | Doetinchem | Netherlands |
| Research Site | Dordrecht | Netherlands |
| Research Site | Drachten | Netherlands |
| Research Site | Ede | Netherlands |
| Research Site | Eindhoven | Netherlands |
| Research Site | Emmen | Netherlands |
| Research Site | Enschede | Netherlands |
| Research Site | Flushing | Netherlands |
| Research Site | Geldrop | Netherlands |
| Research Site | Geleen | Netherlands |
| Research Site | Goes | Netherlands |
| Research Site | Gorinchem | Netherlands |
| Research Site | Gouda | Netherlands |
| Research Site | Haarlem | Netherlands |
| Research Site | Hardenberg | Netherlands |
| Research Site | Heerenveen | Netherlands |
| Research Site | Heerlen | Netherlands |
| Research Site | Hengelo | Netherlands |
| Research Site | Hilversum | Netherlands |
| Research Site | Hoofddorp | Netherlands |
| Research Site | Hoogeveen | Netherlands |
| Research Site | Hoorn | Netherlands |
| Research Site | Leeuwarden | Netherlands |
| Research Site | Leiden | Netherlands |
| Research Site | Leidschendam | Netherlands |
| Research Site | Maastricht | Netherlands |
| Research Site | Nieuwegein | Netherlands |
| Research Site | Nijmegen | Netherlands |
| Research Site | Purmerend | Netherlands |
| Research Site | Roermond | Netherlands |
| Research Site | Roosendaal | Netherlands |
| Research Site | Rotterdam | Netherlands |
| Research Site | Schiedam | Netherlands |
| Research Site | Sneek | Netherlands |
| Research Site | Spijkenisse | Netherlands |
| Research Site | Stadskanaal | Netherlands |
| Research Site | Terneuzen | Netherlands |
| Research Site | The Hague | Netherlands |
| Research Site | Tiel | Netherlands |
| Research Site | Tilburg | Netherlands |
| Research Site | Uden | Netherlands |
| Research Site | Utrecht | Netherlands |
| Research Site | Veldhoven | Netherlands |
| Research Site | Venlo | Netherlands |
| Research Site | Winschoten | Netherlands |
| Research Site | Winterswijk | Netherlands |
| Research Site | Woerden | Netherlands |
| Research Site | Zaandam | Netherlands |
| Research Site | Zevenaar | Netherlands |
| Research Site | Zoetermeer | Netherlands |
| Research Site | Zutphen | Netherlands |
| Research Site | Zwolle | Netherlands |
| Derived |
| van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG). Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. Int J Cancer. 2019 Sep 1;145(5):1325-1333. doi: 10.1002/ijc.32205. Epub 2019 Mar 4. |
| 30588619 | Derived | van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG). Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. Int J Cancer. 2019 Jul 1;145(1):274-283. doi: 10.1002/ijc.32093. Epub 2019 Jan 16. |
| 29031778 | Derived | Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Seynaeve CM; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1502-1511. doi: 10.1016/S1470-2045(17)30600-9. Epub 2017 Oct 12. |
| Prot_000.pdf |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077384 | Anastrozole |
| ID | Term |
|---|---|
| D009570 | Nitriles |
| D009930 | Organic Chemicals |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided